

## Dural arteriovenous fistulas misdiagnosed as intracranial neoplasms: illustrative case

Tobias Rossmann, MD,<sup>1,2</sup> Michael Veldeman, MD, PhD,<sup>1,3</sup> Ville Nurminen, MD, PhD,<sup>1</sup> Rahul Raj, MD, PhD,<sup>1</sup> and Mika Niemelä, MD, PhD<sup>1</sup>

<sup>1</sup>Department of Neurosurgery, Helsinki University Hospital, University of Helsinki, Finland; <sup>2</sup>Department of Neurosurgery, Neuromed Campus, Kepler University Hospital, Linz, Austria; and <sup>3</sup>Department of Neurosurgery, RWTH Aachen University Hospital, Aachen, Germany

**BACKGROUND** Dural arteriovenous fistulas (dAVF) may induce imaging findings attributable to various disease entities including malignant neoplasms. In these cases, diagnosis and adequate treatment are often delayed and patients may be exposed to spurious treatments in addition to the risks inherent to an untreated dAVF with cortical venous drainage.

**OBSERVATIONS** The authors report a case of a patient referred for surgical treatment of a supratentorial high-grade glioma. Thorough review of imaging data challenged the initial radiological diagnosis and led to proper angiographic workup. As a result, a high-grade dAVF was confirmed and successfully embolized. In addition to this case, we provide an extensive literature review on dAVF initially diagnosed as cerebral neoplasms, including clinical, imaging and follow-up data.

**LESSONS** The literature provides diagnostic criteria for dAVF on magnetic resonance imaging; however, those criteria may be only partly applicable in many cases. Misdiagnosis of a neoplasm due to dAVF has been reported but remains rare, especially in supratentorial lesions. Digital subtraction angiography should be pursued to rule out an underlying vascular pathology if any doubt. This may prevent unnecessary interventions such as biopsies, pharmacological treatment and a delay in dAVF treatment, given its associated risk of hemorrhage and nonhemorrhagic neurological deficits.

<https://thejns.org/doi/abs/10.3171/CASE22365>

**KEYWORDS** cortical venous drainage; dAVF; dural arteriovenous fistula; endovascular; glioma; tumor

Dural arteriovenous fistulas (dAVFs) are rare, with a reported incidence of 0.16–0.51 case per 100,000 individuals per year.<sup>1,2</sup> The pattern of venous drainage<sup>3,4</sup> predicts the clinical course in dAVF. If cortical venous drainage is present, 30% of patients will suffer hemorrhage, corresponding to an annual risk of 6%. Thirty percent of patients (4% annual risk) will present with nonhemorrhagic neurological deficits (NHNDs).<sup>5</sup> Although hemorrhage on imaging is usually unambiguous, primary investigation by computed tomography (CT) or magnetic resonance imaging (MRI) in nonhemorrhagic cases may demonstrate findings initially not attributed to dAVF.<sup>6,7</sup> This may lead to incorrect diagnoses and erroneous decisions on further diagnostic and treatment measures.

In the case presented here, first a supratentorial neoplasm was diagnosed and referred for surgical treatment. Fortunately, additional

imaging revealed the correct diagnosis and led to successful occlusion of a high-grade dAVF. In addition to this case, we also provide an extensive literature review on dAVF initially diagnosed as cerebral neoplasms, including clinical, imaging and follow-up data.

### Illustrative Case


A 69-year-old male patient presented without relevant comorbidities or history of trauma, cranial surgery, or infection. MRI done 13 years earlier was unremarkable. While doing sports, the patient experienced a self-limiting generalized seizure. Thereafter, neuro-examination, laboratory tests, and CT (Fig. 1C) were all unremarkable. Despite receiving anticonvulsants, the patient experienced further seizures and was admitted to a

**ABBREVIATIONS** CT = computed tomography; dAVF = dural arteriovenous fistula(s); DSA = digital subtraction angiography; ECA = external carotid artery; MMA = middle meningeal artery; MRA = magnetic resonance angiography; MRI = magnetic resonance imaging; NHND = nonhemorrhagic neurological deficits.

**INCLUDE WHEN CITING** Published November 14, 2022; DOI: 10.3171/CASE22365.

**SUBMITTED** August 26, 2022. **ACCEPTED** September 12, 2022.

© 2022 The authors, CC BY-NC-ND 4.0 (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



**FIG. 1.** Axial T2-weighted (A) and diffusion-weighted (B) images showing vasogenic edema within the swollen posterior part of the superior frontal gyrus. No engorged veins are visible within the gyrus or on the cortical surface. Native CT (C) of the corresponding area.


neurological unit after 8 days. Anticonvulsants were escalated and a noncontrast MRI was performed (Fig. 1A and B), raising suspicions of a left frontal intraaxial tumor. Contrast-enhanced MRI was added (Fig. 2), showing cortical enhancement and increased vascularity and cerebral blood volume. The initial radiological diagnosis was malignant glioma, and the patient was referred to our neurosurgical department for surgery. Further review raised suspicions of a vascular malformation; six-vessel digital subtraction angiography (DSA) then demonstrated a Borden III/Cognard III dAVF (Fig. 3) fed from the frontal branch of the right middle meningeal artery (MMA). The feeder traversed the midline draining into a left frontal bridging vein with retrograde filling of the cortical vein and prominent filling of a deep choroidal drainage. Also, antegrade drainage of the cortical vein toward the left sphenoparietal sinus was visible. No other feeders were present. A slight dilatation of the draining veins was apparent without significant venous ectasia. Transarterial embolization was performed via a right-sided transfemoral access with a long 8-Fr sheath and a Neuron MAX 088 guiding catheter (Penumbra Inc.) placed in the proximal right external carotid artery (ECA). A Phenom Plus distal access catheter (Medtronic Inc.) was advanced to the proximal MMA, an Apollo 5-cm embolization microcatheter (Medtronic Inc.) was used to

inject PHIL 25% (MicroVention Inc.) to the fistulous point. Complete obliteration was confirmed by DSA after the procedure. After treatment, the patient did not experience any neurological deficits, returned to work and was free from seizures with the established anticonvulsant regimen. A follow-up electroencephalogram was within normal limits. On MRI 3 months after embolization, parenchymal findings had disappeared (Fig. 4). Another DSA study will be performed 6 months after embolization to verify total obliteration of the dAVF.


This manuscript was prepared in accordance with CARE guidelines for case reports.

## Discussion


A dAVF initially misdiagnosed as a neoplastic pathology is rare, with the majority of cases accounting for brainstem lesions.<sup>8–18</sup>



**FIG. 2.** Axial (left) and coronal (right) gadolinium-enhanced T1-weighted magnetic resonance images. Patchy cortical contrast enhancement is visible on the lateral aspect of the superior frontal gyrus, which is slightly enlarged by vasogenic edema. A singular corkscrew-like dilated leptomeningeal vessel (white arrow) traverses the lesion, traveling from the cortical surface to the lateral wall of the lateral ventricle. No clusters of vessels around the dural sinus or venous ectasias are visible, the fistula itself is not perceptible, and veno-occlusive disease was not found.



**FIG. 3.** Anteroposterior (A) and lateral (B) views of the early arterial phase of a right ECA angiogram. Asterisk depicts frontal branch of right MMA. White arrows mark the fistula point to a left frontal bridging vein with early retrograde filling. Late arterial phase of the same ECA angiogram (C and D). Black arrowheads show deep venous drainage toward the lateral ventricle wall, and white arrowheads mark antegrade drainage via a cortical vein and the sylvian vein toward the sphenoparietal sinus.



**FIG. 4.** Axial T2-weighted (left) and ADC (right) images 3 months after embolization. Previous parenchyma findings have completely disappeared.

Only three cases of diencephalic,<sup>19–21</sup> two cerebellar<sup>22,23</sup> and two supratentorial lesions<sup>23,24</sup> have been reported. Table 1 provides the results of our literature review. We only included cases in which an intracranial neoplasm was the erroneous primary suspicion but an underlying cerebral dAVF was later revealed.

### Observations

Venous congestion is the true cause of clinical and imaging findings. Of 19 cases reported, four (21%) underwent biopsy of the suspicious lesions, demonstrating parenchymal changes attributable to venous congestion. In the first case,<sup>24</sup> diagnosis of dAVF was already established and surgical treatment was chosen. A biopsy was taken during surgery, exhibiting swollen endothelial cells and nonspecific microgliosis but otherwise normal parenchyma. Another study<sup>21</sup> reports a thalamic biopsy for a suspected neoplasm/lymphoma. The non-neoplastic histology was deemed false-negative, as it showed subacute anoxic damage but otherwise intact thalamic histoarchitecture. Eventually the dAVF was visualized on contrast-enhanced CT by coincidence. In another case report<sup>22</sup> the biopsy of a cerebellar mass showed non-specific reactive changes and the patient was discharged with long-term steroids. A recurrence of symptoms 6 months later led to the correct diagnosis. Roelz et al.<sup>17</sup> describe edematous parenchyma and mild gliosis as a result of a brainstem biopsy prompting empirical steroid treatment with subsequent regression of brainstem dysfunction and imaging findings. An exacerbation of symptoms 8 months later led to the obliteration of a Cognard type V fistula. These cases demonstrate the potential threefold risk patients encounter due to misleading imaging findings, as a high-risk biopsy may lead to long-term pharmacological treatment and delay cure of a lesion prone to hemorrhage.

Although DSA is the gold standard in establishing the correct diagnosis of dAVF, patients with NHNDs may first undergo CT or MRI. Letourneau-Guillon et al.<sup>7</sup> described CT and MRI findings in a cohort of 92 patients harboring dAVF. The presence of dilated leptomeningeal or medullary vessels, venous ectasia, or vasogenic edema were significantly associated with cortical venous reflux. Moreover, dilated extracranial branches of the ECA, clusters of vessels surrounding dural venous sinus, or parenchymal enhancement were also strongly associated. Kwon et al.<sup>6</sup> found dilated leptomeningeal/medullary vessels and vascular enhancement to be significantly related to higher grades of dAVF, whereas white matter hyperintensity was close to significant correlation. In our case, vasogenic edema

and parenchymal enhancement were present (Figs. 1 and 2), whereas the other associated signs were missing. The exact fistula site was not perceptible on contrast-enhanced series, however, the lack of a MRA was a shortcoming in this patient's work-up.

Including our case, contrast-enhancement was reported in 17 of 19 cases (89%; information missing in 2 cases), as shown in Table 1. This is a notably high rate, as for comparison a review of Cognard type V fistulas<sup>17</sup> found enhancement only in 27% of cases. Contrast enhancement may be caused by disruption of the blood-brain-barrier and/or stasis of contrast agent in congested veins<sup>15</sup> and might be one of the main reasons why neoplasms were suspected. Kawaguchi et al.<sup>25</sup> classified different stages of venous ischemia based on MRI findings. Contrast-enhancement was attributed to an advanced stage of congestion that may directly precede hemorrhage. The authors assumed that the underlying changes might still be reversible. However, if enhancement is persistent despite treatment this may then be a sign of potential irreversibility.<sup>15</sup> Including our case, we found full resolution of the neoplasm-suspicious lesions in 8 cases (42%; information missing in 5 cases) and partial improvement in 14 (74%; information missing in 5 cases). This is in line with the assumption that high-grade congestion may be fully reversible on imaging. The rate of complete disappearance may in fact be even higher, given the variable length of reported imaging follow-up ranging from 2 weeks to 3 years. Time interval from symptom onset to treatment seems not to have had an influence.

With regard to clinical symptoms, complete recovery was reported in 11 cases (58%; information missing in 6 cases), whereas partial improvement was found in all patients after final dAVF treatment. The two cases where persistent symptoms were reported, had short follow-up and include a case involving pons, medulla, and cervical cord with a 9-month history of symptoms and requiring multiple interventions.<sup>17</sup> This is also the only case in which neither imaging nor symptoms fully resolved. One might speculate whether full recovery of imaging or symptoms or both may indicate that the underlying pathology has been treated sufficiently. A recent study<sup>26</sup> found a 3% recurrence rate of dAVF initially occluded by endovascular treatment, which should be kept in mind. In our review 3 cases needed retreatment for incomplete obliteration, 1 was due to persistent imaging findings<sup>23</sup> and 1 was due to recurrence of symptoms,<sup>17</sup> whereas technical difficulties caused multiple treatments in the third.

Based on two cases, Ishihara et al.<sup>23</sup> described that the hyperintense signal due to vasogenic edema would normalize faster on the apparent diffusion coefficient (ADC) map than on T2-weighted images. They found this to be of prognostic value whether a dAVF was fully cured or if a residual shunt or recurrence should be evaluated.

We recommend follow-up with both DSA and MRI. In our case DSA was scheduled after 6 months to rule out incomplete obliteration or recurrence. The MRI was scheduled already after 3 months, demonstrating full resolution of the lesion mimicking malignancy, and any ADC and T2 alterations. This also ruled out the slim chance the patient would have both a dAVF and a malignant glioma.

Two more findings specific to this subset of dAVF are noteworthy. Only 6 cases (32%) drained into a dural sinus (2 cavernous; 2 superior petrosal; 1 superior sagittal; 1 transverse sinus), while all others drained into cortical veins, perimedullary veins or had deep venous drainage. This indicates that dAVF mimicking neoplasms represent potentially aggressive fistulas and require immediate

**TABLE 1. Overview of cases and their characteristics**

Case No.	Authors & Year	Age (yrs)	Sex	dAVF Type/ Fistula Location	Initial Suspected Diagnoses	Anatomical Location of Suspicious Lesion	MRI Contrast Enhancement	Symptom Duration	Tx Addressing Initially Suspected Lesion	dAVF Tx	Complete Obliteration After Final Tx	Sxs Improved After Final Tx	Sxs Fully Resolved at Final FU	Suspicious Lesion		
														Suspicious Lesion Resolved at Final Imaging	Duration of Imaging FU for Suspicious Lesion	
1	Present case	69	M	Cortical vein	Glioma	Frontal lobe	Yes	3 wks	No	Endovascular	Yes	Yes	Yes	Yes	3 mos	
2	Goldberg et al., 2016 <sup>24</sup>	56	F	Cortical vein	Neoplasm, vascular	Frontal lobe	Yes	Immediate treatment	Yes (biopsy at fistula occlusion)	Surgery	Yes	Yes	Yes	Yes	14 mos	
3	Ishihara et al., 2009 <sup>23</sup>	75	F	Cortical vein	Neoplasm	Frontal lobe, temporal lobe	Yes	n/a	No	Endovascular	Yes	Yes	Yes	No	6 mos	
4	Borja et al., 2014 <sup>19</sup>	51	M	Vein of Galen (multiple fistulas)	Neoplasm, viral encephalitis	Thalamus (bilateral)	Yes	5 wks	No	Endovascular	Yes	Yes	Yes	n/a	n/a	
5	Matsumura et al., 2008 <sup>20</sup>	73	M	Vein of Galen	Glia tumor, metabolic encephalopathy	Thalamus (bilateral)	n/a	5 mos	No	Endovascular	n/a	Yes	n/a	Yes	10 mos	
6	Sugrue et al., 2009 <sup>21</sup>	51	M	Superior sagittal sinus	Malignant neoplasm, lymphoma	Thalamus (bilateral)	Yes	6 mos	Yes (biopsy)	Endovascular	Yes	Yes	Yes	n/a	3 mos	
7	Bernard et al., 2018 <sup>8</sup>	65	F	Perimedullary vein	Infiltrative glioma	Medulla, cervical spinal cord	Yes	5 mos	No	Surgery	Yes	Yes	Yes	n/a	n/a	
8	Chen et al., 2019 <sup>9</sup>	66	M	Perimedullary vein	Neoplasm, infectious, inflammatory	Pons, medulla	Yes	1 mo	No	Endovascular (small residual shunt)	No	Yes	n/a	Yes	No	3 mos
9	Crum & Link, 2004 <sup>10</sup>	35	M	Perimedullary vein	Neoplasm	Medulla	Yes	"several wks"	No	Surgery	Yes	Yes	No	Yes	Yes	3 mos
10	Duan et al., 2017 <sup>11</sup>	67	F	Superior petrosal sinus	Neoplasm	Pons, cerebellum	Yes	1 mo	No	Endovascular	n/a	Yes	n/a	Yes	No	"several wks"
11	Iwasaki et al., 2006 <sup>12</sup>	71	F	Cavernous sinus	Malignant neoplasm	Pons	Yes	5 mos	No	Endovascular (twice) + SRS*	Yes*	Yes	Yes	Yes	Yes	3 years
12	Le Guennec et al., 2015 <sup>13</sup>	36	M	Perimedullary vein	Malignant glioma	Medulla	Yes	2 mos	No	Endovascular	Yes	Yes	Yes	Yes	Yes	6 mos
13	Nambu et al., 2020 <sup>14</sup>	77	F	Cavernous sinus	Malignant neoplasm	Pons	Yes	2 mos	No	Endovascular	Yes	Yes	n/a	Yes	Yes	5 mos
14	Patsalides et al., 2010 <sup>15</sup>	53	M				Yes	3 mos	No	Endovascular	Yes	Yes	Yes	Yes	No	3 mos

CONTINUED ON PAGE 5 »

**TABLE 1. Overview of cases and their characteristics**

Case No.	Authors & Year	Age (yrs)	Sex	dAVF Type/ Fistula Location	Initial Suspected Diagnoses	Anatomical Location of Suspicious Lesion	MRI Contrast Enhancement	Symptom Duration Until 1st dAVF Tx	Tx Addressing Initially Suspected Lesion	dAVF Tx	Complete Obliteration After Final Tx	Sxs Improved After Final Tx	Sxs Fully Resolved at Final FU	Suspicious Lesion Improved After Tx	Suspicious Lesion Fully Resolved at Final Imaging	Duration of Imaging FU for Suspicious Lesion
15	Probst et al., 1994 <sup>16</sup>	40	F	Transverse sinus	Neoplasm, encephalitis, demyelination	Pons, medulla, cervical spinal cord	Yes	n/a	No	Endovascular + surgery	Yes	Yes	Yes	n/a	n/a	n/a
16	Roelz et al., 2015 <sup>17</sup>	76	M	Perimedullary vein	Glioma, lymphoma, inflammatory	Pons, medulla, cervical spinal cord	Yes	9 mos	Yes (biopsy)	Endovascular (twice) + surgery*	Yes*	Yes	No	Yes	No	2 wks
17	Weigle et al., 2002 <sup>18</sup>	53	M	Vein of Galen	Brainstem glioma	Pons, mesencephalon, thalamus (bilateral)	n/a	"several mos"	No	Endovascular	Yes	Yes	Yes	Yes	Yes	6 mos
18	Cho et al., 2018 <sup>22</sup>	49	M	Cortical vein	Neoplasm	Cerebellum	Yes	6 mos	Yes (biopsy)	Surgery	n/a	Yes	n/a	n/a	n/a	n/a
19	Ishihara et al., 2009 <sup>23</sup>	68	M	Cortical vein	Ischemia, neoplasm	Cerebellum	Yes	n/a	No	Endovascular (twice)*	Yes*	Yes	n/a	n/a	No	3 mos

FU = follow-up; n/a = information not available in the reference; SRS = stereotactic radiosurgery; Sxs = symptoms; Tx = treatment.

\* Marks cases that needed repetitive treatment due to incomplete initial occlusion or recurrence.



establishment of correct diagnosis and subsequent treatment. Furthermore, the anatomical location of the supposed neoplasm was not indicative of the fistula location. Enhancing brainstem lesions may be caused by dAVF draining into perimedullary veins, cavernous sinus, vein of Galen and transverse or superior petrosal sinus. Two of three bithalamic lesions had dAVF draining into the vein of Galen, while the latter drained to the distal superior sagittal sinus.

This report is limited by variable terminology used in some case reports, imaging data limited to singular pictures and follow-up data not provided. To the best of our knowledge, this is the most extensive literature review on this topic, reporting fistula types, course of treatment, symptoms, and radiological findings.

## Lessons

The literature provides diagnostic criteria for dAVF in MRI, however, those may only be partly applicable in many cases. Misdiagnosis of a neoplasm due to dAVF has been reported, but remains rare, especially in supratentorial lesions. DSA should be pursued to rule out an underlying vascular pathology if any doubt. This may prevent unnecessary interventions such as biopsies, pharmacological treatment and a delay in dAVF treatment, given its associated risk of hemorrhage and NHND.

## References

1. Al-Shahi R, Bhattacharya JJ, Currie DG, et al. Prospective, population-based detection of intracranial vascular malformations in adults: the Scottish Intracranial Vascular Malformation Study (SIVMS). *Stroke*. 2003;34(5):1163–1169.
2. Piippo A, Niemelä M, van Popta J, et al. Characteristics and long-term outcome of 251 patients with dural arteriovenous fistulas in a defined population. *J Neurosurg*. 2013;118(5):923–934.
3. Borden JA, Wu JK, Shucart WA. A proposed classification for spinal and cranial dural arteriovenous fistulous malformations and implications for treatment. *J Neurosurg*. 1995;82(2):166–179.
4. Cognard C, Gobin YP, Pierot L, et al. Cerebral dural arteriovenous fistulas: clinical and angiographic correlation with a revised classification of venous drainage. *Radiology*. 1995;194(3):671–680.
5. Gross BA, Du R. The natural history of cerebral dural arteriovenous fistulae. *Neurosurgery*. 2012;71(3):594–602, discussion 602–603.
6. Kwon BJ, Han MH, Kang HS, Chang KH. MR imaging findings of intracranial dural arteriovenous fistulas: relations with venous drainage patterns. *AJNR Am J Neuroradiol*. 2005;26(10):2500–2507.
7. Letourneau-Guillon L, Cruz JP, Krings T. CT and MR imaging of non-cavernous cranial dural arteriovenous fistulas: Findings associated with cortical venous reflux. *Eur J Radiol*. 2015;84(8):1555–1563.
8. Bernard F, Lemée JM, Faguer R, Fournier HD. Lessons to be remembered from a dural arteriovenous fistula mimicking medulla and high cervical cord glioma. *World Neurosurg*. 2018;113:312–315.
9. Chen PY, Juan YH, Lin SK. An isolated unilateral pontomedullary lesion due to an intracranial dural arteriovenous fistula mimicking a brain tumor - Case and review. *J Nippon Med Sch*. 2019;86(1):48–54.
10. Crum BA, Link M. Intracranial dural arteriovenous fistula mimicking brainstem neoplasm. *Neurology*. 2004;62(12):2330–2331.
11. Duan SS, Liu H, Wang WL, Zhao CB. A case of intracranial dural arteriovenous fistula mimicking brainstem tumor. *Chin Med J (Engl)*. 2017;130(20):2519–2520.
12. Iwasaki M, Murakami K, Tomita T, Numagami Y, Nishijima M. Cavernous sinus dural arteriovenous fistula complicated by pontine venous congestion. A case report. *Surg Neurol*. 2006;65(5):516–519.
13. Le Guennec L, Leclercq D, Szatmary Z, et al. Dural arteriovenous fistula mimicking a brainstem glioma. *J Neuroimaging*. 2015;25(6):1053–1055.
14. Nambu K, Misaki K, Yoshikawa A, et al. Cavernous sinus dural arteriovenous fistula with an enhanced lesion in the brainstem mimicking a malignant tumor. *World Neurosurg*. 2020;140:13–17.
15. Patsalides A, Tzatha E, Stübgen JP, Shungu DC, Stieg PE, Gobin YP. Intracranial dural arteriovenous fistula presenting as an enhancing lesion of the medulla. *J Neurointerv Surg*. 2010;2(4):390–393.
16. Probst EN, Christante L, Zeumer H. Brain-stem venous congestion due to a dural arteriovenous fistula in the posterior fossa. *J Neurol*. 1994;241(3):175–177.
17. Roelz R, Van Velthoven V, Reinacher P, et al. Unilateral contrast-enhancing pontomedullary lesion due to an intracranial dural arteriovenous fistula with perimedullary spinal venous drainage: the exception that proves the rule. *J Neurosurg*. 2015;123(6):1534–1539.
18. Weigele JB, Chaloupka JC, Lesley WS. Galenic dural arteriovenous fistula: unusual clinical presentation and successful endovascular therapy. Case report. *J Neurosurg*. 2002;97(2):467–470.
19. Borja MJ, Schaefer PW, Boulter DJ. Case of the season: dural arteriovenous fistula mimicking a bithalamic neoplasm or viral encephalitis. *Semin Roentgenol*. 2014;49(1):4–9.
20. Matsumura A, Oda M, Hozuki T, Imai T, Shimohama S. Dural arteriovenous fistula in a case of dementia with bithalamic MR lesions. *Neurology*. 2008;71(19):1553.
21. Sugrue PA, Hurley MC, Bendok BR, et al. High-grade dural arteriovenous fistula simulating a bilateral thalamic neoplasm. *Clin Neurol Neurosurg*. 2009;111(7):629–632.
22. Cho SM, Buletko AB, Patel P, Cerejo R, Bain M. A case of dural arteriovenous fistula mimicking a cerebellar tumor. *Neurohospitalist*. 2018;8(3):158–159.
23. Ishihara H, Ishihara S, Okawara M, et al. Two cases of a dural arteriovenous fistula mimicking a brain tumor. *Interv Neuroradiol*. 2009;15(1):77–80.
24. Goldberg J, Beck J, Bervini D. Dural arteriovenous fistula mimicking a supratentorial Tumor. *World Neurosurg*. 2016;92:585.e1–585.e3.
25. Kawaguchi T, Kawano T, Kaneko Y, Ooasa T, Tsutsumi M, Ogasawara S. Classification of venous ischaemia with MRI. *J Clin Neurosci*. 2001;8(suppl 1):82–88.
26. Gross BA, Albuquerque FC, Moon K, McDougall CG. Evolution of treatment and a detailed analysis of occlusion, recurrence, and clinical outcomes in an endovascular library of 260 dural arteriovenous fistulas. *J Neurosurg*. 2017;126(6):1884–1893.

## Disclosures

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

## Author Contributions

Conception and design: Rossmann, Niemelä. Acquisition of data: Rossmann, Veldeman, Nurminen, Raj. Analysis and interpretation of data: Rossmann, Veldeman, Raj, Niemelä. Drafting the article: Rossmann. Critically revising the article: all authors. Reviewed submitted version of manuscript: Rossmann, Veldeman, Niemelä. Approved the final version of the manuscript on behalf of all authors: Rossmann. Statistical analysis: Rossmann. Administrative/technical/material support: Raj, Niemelä. Study supervision: Niemelä.

## Correspondence

Tobias Rossmann: Helsinki University Hospital, University of Helsinki, Finland. t\_rossmann@gmx.net.